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Background: We previously reported 6 patients with
Marfan-like phenotype due to transforming growth factor
b-receptor 2 (TGFBR2) mutations (Am J Med Genet Part
A 149A:1452-1459). Loeys-Dietz syndrome (LDS) is a
recently described autosomal dominant connective tissue
disorder characterized by facial dysmorphism, cleft palate,
aortic dilatation, blood vessel tortuosity and a high risk of
aortic dissection. It is caused by mutations in the TGFBR1
and 2 genes. Two of the 6 patients reported in 2009 were
re-assessed and confirmed to have phenotypic features of
LDS.
Clinical information: K.T.H. and T.W.S. (Patient 4 and
5 in AJMG 149A:1452-1459) both presented with
asymptomatic murmur and marfanoid features in their
childhood. In addition they have unique craniofacial
features including craniosynostosis, hypertelorism and bifid
uvula. They did not fulfill the Ghent or modified Ghent
criteria. Both have significant progressive aortic root
dilatation requiring surgical replacement in adolescence.
K.T.H. had a missense mutation c.1069G>A/p.G357R in
TGFBR2 gene while T.W.S. also had a missense mutation
c.973A>C/p.T325P in the same gene.
Conclusion: The arterial involvement of LDS is more
extensive and the propensity to rupture is higher when
compared to Marfan syndrome. A third of LDS patients
can presented with aortic dissection or death before 19 years
of age. The youngest age of presentation was 6 months and
aortic dissection can occur when the aortic root is <4 cm.
LDS patients are also prone to cerebral/abdominal arterial
dissection and cervical spine instabilities. It is important to
recognize LDS as a differential diagnosis of Marfan-like
phenotypes so that accurate genetic counseling, lifelong
surveillance and timely surgical intervention can be offered.
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Background: Radix Astragali, a major component of
Danggui Buxue Tang (DBT) decoctions, is extensively used
in Chinese medicine and is  known to promote
haematopoiesis in vivo and in vitro. Astragaloside IV (AS-
IV) is one of the major compounds of Radix Astragali. As
the major compound involved in DBT, whether it is
responsible for the haematopoiesis enhancement of DBT
remains unknown. Therefore, we investigated the function
of AS-IV by an in vitro haemotopoiesis model and explored
the possible underlying cell signaling mechanism.
Design and methods: Murine colony forming units
(CFU) assays were used to determine the effects of AS-IV
on haematopoiesis in vitro. K562 cells were used as a
haematopoietic cell model in vitro to explore the possible
molecular mechanisms underlying AS-IV's activity.
Phosphorylation of EKR1/2 (pEKR1/2) quantification were
analyzed by flow cytometry, which included: 1) a control
group; 2) AS-IV treatment group; 3) inhibitor groups with
PD98059 or Gefinitib; 4) and a combination treatment
group of the corresponding inhibitor and AS-IV.
Meanwhile, cells proliferation was analyzed using 3H-
Thymidine radioactive assay and the examinations of cells'
survival percentage were analyzed by Annexin V/PI staining
using flow cytometry. The pEKR1/2, tEKR1/2, Bcl-2 and
Bax expression were analyzed by western blot.
Results: AS-IV promoted the formation of bone marrow
colony forming units (CFUs) in erythrocytes, granulocytes,
monocytes in vitro. AS-IV also significantly enhanced CFU-
megakaryocytes (MK) formation. However, CFU-MK
formation was significantly reduced by PD98059,
suggesting that ERK1/2 activating process was one of the
main pathways of AS-IV action. In K562 cells, AS-IV also
promoted cell proliferation, prolonged S-phase (DNA
synthesis) and prevented cells from apoptosis. The impact
of EFGR inhibitor Gefinitib on the ERK1/2 phosphorylation
process was further investigated. We demonstrated that AS-
IV acted via the EGFR-ERK1/2 signalling pathway, which
up-regulated the anti-apoptotic protein Bcl-2 expression
through the ERK1/2 phosphorylation.
Conclusion: We found that astragaloside IV promoted
haematopoiesis in vitro and this is possibly in part via
activation of the EGFR-EKR1/2 signaling pathway.
